Ropinirole is effective on motor function when used as an adjunct to levodopa in Parkinson's disease: STRONG study

Yoshikuni Mizuno; Takashi Abe; Kazuko Hasegawa; Sadako Kuno; Tomoyoshi Kondo; Mitsutoshi Yamamoto; Mitsuyoshi Nakashima; Ichiro Kanazawa; S. Honma; M. Baba; I. Toyoshima; H. Onodera; I. Nakano; H. Nomura; K. Yamane; S. Tanaka; H. Yoshino; A. Ueki; F. Yokochi; M. Tamaki; M. Yokochi; H. Utsumi; M. Iwata; M. Kawai; T. Hashimoto; J. Teramoto; T. Atsumi; M. Takahashi; Y. Mitsui; T. Matsubara; T. Azuma; S. Matsumoto; H. Tachibana; K. Hiyama; K. Abe; K. Nakashima; I. Kohhira; M. Nomoto; T. Yamada

doi:10.1002/mds.21313

Ropinirole is effective on motor function when used as an adjunct to levodopa in Parkinson's disease: STRONG study

Yoshikuni Mizuno, Takashi Abe, Kazuko Hasegawa, Sadako Kuno, Tomoyoshi Kondo, Mitsutoshi Yamamoto, Mitsuyoshi Nakashima, Ichiro Kanazawa, S. Honma, M. Baba, I. Toyoshima, H. Onodera, I. Nakano, H. Nomura, K. Yamane, S. Tanaka, H. Yoshino, A. Ueki, F. Yokochi, M. TamakiM. Yokochi, H. Utsumi, M. Iwata, M. Kawai, T. Hashimoto, J. Teramoto, T. Atsumi, M. Takahashi, Y. Mitsui, T. Matsubara, T. Azuma, S. Matsumoto, H. Tachibana, K. Hiyama, K. Abe, K. Nakashima, I. Kohhira, M. Nomoto, T. Yamada

Research output: Contribution to journal › Article

30 Citations (Scopus)

Abstract

We report the results of a randomized, double-blind, placebo-controlled, 16-week study to evaluate the efficacy and safety of ropinirole, 0.75 to 15.0 mg/day, as an adjunct to levodopa. A total of 243 patients were randomly assigned into placebo or ropinirole groups. The mean (standard deviation) dose of ropinirole at endpoint was 7.12 (2.88) mg/day. The primary endpoint - the mean reduction in the Unified Parkinson's Disease Rating Scale (UPDRS) total motor score - was significantly greater for the ropinirole group than the placebo group (-9.5 vs. -4.5, P = 0.00001). The mean reduction in the UPDRS total activities of daily living (ADL) score was also significantly greater for ropinirole than for placebo (-2.7 vs. -1.0, P = 0.0002). The percentage of patients showing at least a 20% reduction in the percentage of time spent "off was significantly greater for the ropinirole group than for the placebo group (58.7% vs. 38.6%, P = 0.030). A total of 84.3 and 65.6% of the patients experienced adverse events while receiving ropinirole or placebo, respectively. The results showed that ropinirole was more effective than placebo in improving motor function and ADL when used as an adjunct to levodopa in patients with advanced Parkinson's disease.

Original language	English
Pages (from-to)	1860-1865
Number of pages	6
Journal	Movement Disorders
Volume	22
Issue number	13
DOIs	https://doi.org/10.1002/mds.21313
Publication status	Published - Oct 15 2007

Fingerprint

Keywords

L-dopa
Parkinson's disease
Randomized controlled study
Ropinirole
Treatment

ASJC Scopus subject areas

Neurology
Clinical Neurology

Cite this

Mizuno, Y., Abe, T., Hasegawa, K., Kuno, S., Kondo, T., Yamamoto, M., Nakashima, M., Kanazawa, I., Honma, S., Baba, M., Toyoshima, I., Onodera, H., Nakano, I., Nomura, H., Yamane, K., Tanaka, S., Yoshino, H., Ueki, A., Yokochi, F., ... Yamada, T. (2007). Ropinirole is effective on motor function when used as an adjunct to levodopa in Parkinson's disease: STRONG study. Movement Disorders, 22(13), 1860-1865. https://doi.org/10.1002/mds.21313

Ropinirole is effective on motor function when used as an adjunct to levodopa in Parkinson's disease : STRONG study. / Mizuno, Yoshikuni; Abe, Takashi; Hasegawa, Kazuko; Kuno, Sadako; Kondo, Tomoyoshi; Yamamoto, Mitsutoshi; Nakashima, Mitsuyoshi; Kanazawa, Ichiro; Honma, S.; Baba, M.; Toyoshima, I.; Onodera, H.; Nakano, I.; Nomura, H.; Yamane, K.; Tanaka, S.; Yoshino, H.; Ueki, A.; Yokochi, F.; Tamaki, M.; Yokochi, M.; Utsumi, H.; Iwata, M.; Kawai, M.; Hashimoto, T.; Teramoto, J.; Atsumi, T.; Takahashi, M.; Mitsui, Y.; Matsubara, T.; Azuma, T.; Matsumoto, S.; Tachibana, H.; Hiyama, K.; Abe, K.; Nakashima, K.; Kohhira, I.; Nomoto, M.; Yamada, T.

In: Movement Disorders, Vol. 22, No. 13, 15.10.2007, p. 1860-1865.

Research output: Contribution to journal › Article

Mizuno, Y, Abe, T, Hasegawa, K, Kuno, S, Kondo, T, Yamamoto, M, Nakashima, M, Kanazawa, I, Honma, S, Baba, M, Toyoshima, I, Onodera, H, Nakano, I, Nomura, H, Yamane, K, Tanaka, S, Yoshino, H, Ueki, A, Yokochi, F, Tamaki, M, Yokochi, M, Utsumi, H, Iwata, M, Kawai, M, Hashimoto, T, Teramoto, J, Atsumi, T, Takahashi, M, Mitsui, Y, Matsubara, T, Azuma, T, Matsumoto, S, Tachibana, H, Hiyama, K, Abe, K, Nakashima, K, Kohhira, I, Nomoto, M & Yamada, T 2007, 'Ropinirole is effective on motor function when used as an adjunct to levodopa in Parkinson's disease: STRONG study', Movement Disorders, vol. 22, no. 13, pp. 1860-1865. https://doi.org/10.1002/mds.21313

Mizuno, Yoshikuni ; Abe, Takashi ; Hasegawa, Kazuko ; Kuno, Sadako ; Kondo, Tomoyoshi ; Yamamoto, Mitsutoshi ; Nakashima, Mitsuyoshi ; Kanazawa, Ichiro ; Honma, S. ; Baba, M. ; Toyoshima, I. ; Onodera, H. ; Nakano, I. ; Nomura, H. ; Yamane, K. ; Tanaka, S. ; Yoshino, H. ; Ueki, A. ; Yokochi, F. ; Tamaki, M. ; Yokochi, M. ; Utsumi, H. ; Iwata, M. ; Kawai, M. ; Hashimoto, T. ; Teramoto, J. ; Atsumi, T. ; Takahashi, M. ; Mitsui, Y. ; Matsubara, T. ; Azuma, T. ; Matsumoto, S. ; Tachibana, H. ; Hiyama, K. ; Abe, K. ; Nakashima, K. ; Kohhira, I. ; Nomoto, M. ; Yamada, T. / Ropinirole is effective on motor function when used as an adjunct to levodopa in Parkinson's disease : STRONG study. In: Movement Disorders. 2007 ; Vol. 22, No. 13. pp. 1860-1865.

@article{9c8a81dcc38b460597f424202810177f,

title = "Ropinirole is effective on motor function when used as an adjunct to levodopa in Parkinson's disease: STRONG study",

abstract = "We report the results of a randomized, double-blind, placebo-controlled, 16-week study to evaluate the efficacy and safety of ropinirole, 0.75 to 15.0 mg/day, as an adjunct to levodopa. A total of 243 patients were randomly assigned into placebo or ropinirole groups. The mean (standard deviation) dose of ropinirole at endpoint was 7.12 (2.88) mg/day. The primary endpoint - the mean reduction in the Unified Parkinson's Disease Rating Scale (UPDRS) total motor score - was significantly greater for the ropinirole group than the placebo group (-9.5 vs. -4.5, P = 0.00001). The mean reduction in the UPDRS total activities of daily living (ADL) score was also significantly greater for ropinirole than for placebo (-2.7 vs. -1.0, P = 0.0002). The percentage of patients showing at least a 20% reduction in the percentage of time spent {"}off was significantly greater for the ropinirole group than for the placebo group (58.7% vs. 38.6%, P = 0.030). A total of 84.3 and 65.6% of the patients experienced adverse events while receiving ropinirole or placebo, respectively. The results showed that ropinirole was more effective than placebo in improving motor function and ADL when used as an adjunct to levodopa in patients with advanced Parkinson's disease.",

keywords = "L-dopa, Parkinson's disease, Randomized controlled study, Ropinirole, Treatment",

author = "Yoshikuni Mizuno and Takashi Abe and Kazuko Hasegawa and Sadako Kuno and Tomoyoshi Kondo and Mitsutoshi Yamamoto and Mitsuyoshi Nakashima and Ichiro Kanazawa and S. Honma and M. Baba and I. Toyoshima and H. Onodera and I. Nakano and H. Nomura and K. Yamane and S. Tanaka and H. Yoshino and A. Ueki and F. Yokochi and M. Tamaki and M. Yokochi and H. Utsumi and M. Iwata and M. Kawai and T. Hashimoto and J. Teramoto and T. Atsumi and M. Takahashi and Y. Mitsui and T. Matsubara and T. Azuma and S. Matsumoto and H. Tachibana and K. Hiyama and K. Abe and K. Nakashima and I. Kohhira and M. Nomoto and T. Yamada",

year = "2007",

month = oct,

day = "15",

doi = "10.1002/mds.21313",

language = "English",

volume = "22",

pages = "1860--1865",

journal = "Movement Disorders",

issn = "0885-3185",

publisher = "John Wiley and Sons Inc.",

number = "13",

}

TY - JOUR

T1 - Ropinirole is effective on motor function when used as an adjunct to levodopa in Parkinson's disease

T2 - STRONG study

AU - Mizuno, Yoshikuni

AU - Abe, Takashi

AU - Hasegawa, Kazuko

AU - Kuno, Sadako

AU - Kondo, Tomoyoshi

AU - Yamamoto, Mitsutoshi

AU - Nakashima, Mitsuyoshi

AU - Kanazawa, Ichiro

AU - Honma, S.

AU - Baba, M.

AU - Toyoshima, I.

AU - Onodera, H.

AU - Nakano, I.

AU - Nomura, H.

AU - Yamane, K.

AU - Tanaka, S.

AU - Yoshino, H.

AU - Ueki, A.

AU - Yokochi, F.

AU - Tamaki, M.

AU - Yokochi, M.

AU - Utsumi, H.

AU - Iwata, M.

AU - Kawai, M.

AU - Hashimoto, T.

AU - Teramoto, J.

AU - Atsumi, T.

AU - Takahashi, M.

AU - Mitsui, Y.

AU - Matsubara, T.

AU - Azuma, T.

AU - Matsumoto, S.

AU - Tachibana, H.

AU - Hiyama, K.

AU - Abe, K.

AU - Nakashima, K.

AU - Kohhira, I.

AU - Nomoto, M.

AU - Yamada, T.

PY - 2007/10/15

Y1 - 2007/10/15

N2 - We report the results of a randomized, double-blind, placebo-controlled, 16-week study to evaluate the efficacy and safety of ropinirole, 0.75 to 15.0 mg/day, as an adjunct to levodopa. A total of 243 patients were randomly assigned into placebo or ropinirole groups. The mean (standard deviation) dose of ropinirole at endpoint was 7.12 (2.88) mg/day. The primary endpoint - the mean reduction in the Unified Parkinson's Disease Rating Scale (UPDRS) total motor score - was significantly greater for the ropinirole group than the placebo group (-9.5 vs. -4.5, P = 0.00001). The mean reduction in the UPDRS total activities of daily living (ADL) score was also significantly greater for ropinirole than for placebo (-2.7 vs. -1.0, P = 0.0002). The percentage of patients showing at least a 20% reduction in the percentage of time spent "off was significantly greater for the ropinirole group than for the placebo group (58.7% vs. 38.6%, P = 0.030). A total of 84.3 and 65.6% of the patients experienced adverse events while receiving ropinirole or placebo, respectively. The results showed that ropinirole was more effective than placebo in improving motor function and ADL when used as an adjunct to levodopa in patients with advanced Parkinson's disease.

AB - We report the results of a randomized, double-blind, placebo-controlled, 16-week study to evaluate the efficacy and safety of ropinirole, 0.75 to 15.0 mg/day, as an adjunct to levodopa. A total of 243 patients were randomly assigned into placebo or ropinirole groups. The mean (standard deviation) dose of ropinirole at endpoint was 7.12 (2.88) mg/day. The primary endpoint - the mean reduction in the Unified Parkinson's Disease Rating Scale (UPDRS) total motor score - was significantly greater for the ropinirole group than the placebo group (-9.5 vs. -4.5, P = 0.00001). The mean reduction in the UPDRS total activities of daily living (ADL) score was also significantly greater for ropinirole than for placebo (-2.7 vs. -1.0, P = 0.0002). The percentage of patients showing at least a 20% reduction in the percentage of time spent "off was significantly greater for the ropinirole group than for the placebo group (58.7% vs. 38.6%, P = 0.030). A total of 84.3 and 65.6% of the patients experienced adverse events while receiving ropinirole or placebo, respectively. The results showed that ropinirole was more effective than placebo in improving motor function and ADL when used as an adjunct to levodopa in patients with advanced Parkinson's disease.

KW - L-dopa

KW - Parkinson's disease

KW - Randomized controlled study

KW - Ropinirole

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=36248982041&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=36248982041&partnerID=8YFLogxK

U2 - 10.1002/mds.21313

DO - 10.1002/mds.21313

M3 - Article

C2 - 17618525

AN - SCOPUS:36248982041

VL - 22

SP - 1860

EP - 1865

JO - Movement Disorders

JF - Movement Disorders

SN - 0885-3185

IS - 13

ER -

Access to Document

10.1002/mds.21313